BioCryst Pharmaceuticals
BCRX
$4.16
Share price
0.00%
Change (1 day)
-45.41%
Change (1 year)
Categories
BioCryst Pharmaceuticals (BCRX) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.97 B
According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are $0.97 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.97 B | 15.14% |
| 2022-12-31 | $0.84 B | 21.5% |
| 2021-12-31 | $0.69 B | 96.38% |
| 2020-12-31 | $0.35 B | 158.32% |
| 2019-12-31 | $0.13 B | 40.39% |
| 2018-12-31 | $97.6 M | 3.3% |
| 2017-12-31 | $94.49 M | 7.05% |
| 2016-12-31 | $88.26 M | 18.27% |
| 2015-12-31 | $74.63 M | 21.87% |
| 2014-12-31 | $61.23 M | 22.5% |
| 2013-12-31 | $49.99 M | -13.65% |
| 2012-12-31 | $57.89 M | -14.11% |
| 2011-12-31 | $67.4 M | 53.38% |
| 2010-12-31 | $43.94 M | -21.42% |
| 2009-12-31 | $55.92 M | 46.15% |
| 2008-12-31 | $38.26 M | -50.82% |
| 2007-12-31 | $77.81 M | 64.4% |
| 2006-12-31 | $47.33 M | 15.98% |
| 2005-12-31 | $40.8 M | 1201.96% |
| 2004-12-31 | $3.13 M | 90.14% |
| 2003-12-31 | $1.64 M | 40.65% |
| 2002-12-31 | $1.17 M | -48.66% |
| 2001-12-31 | $2.28 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $39.37 B | 3,949.00% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $58.82 B | 5,948.95% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $2.40 B | 147.33% | 🇺🇸 USA |
 Repligen
RGEN | $0.85 B | -12.27% | 🇺🇸 USA |
 Novavax NVAX | $2.51 B | 158.56% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $36.45 M | -96.25% | 🇺🇸 USA |
 NanoViricides NNVC | $0.95 M | -99.90% | 🇺🇸 USA |
 Cel-Sci
CVM | $16.06 M | -98.35% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $1.17 B | 20.71% | 🇺🇸 USA |